Thai FDA Review Timelines: Statutory Ceilings and Practical Reality
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
How long does Thai registration review take? The answer divides into two segments: an e-Submission completeness check of about 15 days, followed by substantive review whose official ceiling depends on the class. Understanding both segments — and the fact that the ceilings are ceilings, not predictions — is the foundation of any realistic Thai schedule.
1. Key takeaways
The Thai review clock runs in two stages, with class-specific statutory ceilings and two known accelerators. The essentials follow.
- Segment one: e-Submission completeness check, about 15 days. After submission, the authority first verifies dossier completeness; only on passing does substantive review begin. These 15 days act as a fast filter — incomplete documentation is intercepted within two weeks rather than discovered after months of waiting.
- Segment two: substantive review, with official ceilings by class: Class 1 (Listing) 200 days, with Positive List devices auto-approved; Class 2 (Notification) 250 days; Class 3 (Notification) 250 days; Class 4 (Licensing) 300 days.
- The 200/250/300 figures are officially listed ceilings, not typical durations. Industry experience indicates that actual review periods generally run faster than the officially listed periods.
- The other side of the coin: disorganised dossiers can take months and pass through multiple deficiency rounds — the ceilings are rarely reached, but deficiency round-trips are common. Dossier quality determines the actual duration more than the nominal class does.
- Two accelerators with known magnitudes: Reliance on the Singapore HSA reduces the standard 150 working days to 60 working days and waives the expert review (saving about 53,000 baht); and Class 1 Positive List auto-approval, granted automatically after submission and fee payment with no human review.
- Unlike Vietnam, which imposes a hard constraint of a 90-day window and a three-deficiency cap with re-application required beyond it, Thailand has no published quantified cap of the same kind on deficiency rounds. This does not license trial and error: each round-trip resets part of the clock, and the real loss is counted in months.
2. Legal basis
The review ceilings and the completeness-check stage derive from the time limits published by the Thai FDA; the auto-approval mechanism for Positive List Class 1 devices rests on the official announcement of January 2025; and the Reliance route rests on the Thai FDA reliance announcement of June 4, 2024 (B.E. 2567), under which the Singapore HSA arrangement reduces review from 150 working days to 60 working days and waives the expert review, saving about 53,000 baht. The class-by-class ceilings are summarised below.
| Class | Pathway | Official time limit ceiling |
| Class 1 | Listing | 200 days (Positive List devices: auto-approval) |
| Class 2 | Notification | 250 days |
| Class 3 | Notification | 250 days |
| Class 4 | Licensing | 300 days |
3. Expert insights
The central insight is that the published ceilings are boundaries, not forecasts. Industry experience shows that real review periods generally run faster than the officially listed periods, yet the same experience records that disorganised dossiers consume months in repeated deficiency exchanges. A more accurate formulation than either number: dossier quality determines the actual duration more than the nominal class does. A carefully built Class 4 file can outperform a sloppy Class 2 file on the calendar, even though the former carries a higher ceiling.
On deficiency management, the absence of a published quantified cap in Thailand — in contrast with Vietnam, where a 90-day window, a three-time cap and mandatory re-application beyond it are hard constraints — does not make deficiency rounds cheap. Each round-trip resets part of the clock and costs months in practice. The correct posture is to build the CSDT correctly the first time and push the number of deficiency rounds to the minimum, not to budget for repeated corrections. In scheduling terms this means the buffer belongs in the plan as a bounded allowance — one round — while the dossier itself is treated as a first-time-right deliverable. A team that plans for several correction cycles has accepted a slower project before the review even begins, and the calendar will oblige.
A further point on the two segments: the 15-day completeness check rewards preparation hygiene more than technical depth. Files that fail there are typically incomplete rather than weak — a missing report, an unsigned declaration or an unaligned annex — and the interception, while annoying, is cheap compared with the same gap discovered months into substantive review. Treating the completeness check as a self-imposed internal gate before submission converts it from a risk into a confirmation step.
4. Practical recommendations
- Compress the total cycle through four levers: build the Full-route base dossier first and subtract for the chosen route (see article 15); assess accelerated pathway eligibility first (see article 14); start establishment licence work as early as possible, since the site inspection is the incompressible element (see article 07); and advance Thai-language localisation in parallel, a hard requirement for home-use devices (see article 27).
- When scheduling, do not plan backwards from the official ceilings alone, and do not rely on the fastest published case either. Use a three-stage schedule model: front-end work (establishment licence plus Thai localisation) + review (estimated at 60 percent of the class ceiling) + a one-round deficiency buffer.
- This model is far more robust than any single number, because it accommodates both the faster-than-ceiling norm and the occasional correction cycle.
- Treat the 15-day completeness check as a quality gate: any interception there is cheap compared with a deficiency discovered months into substantive review.
- For every project, evaluate the two known accelerators — HSA Reliance (60 working days) and Positive List auto-approval — before accepting a standard-route schedule.
- Where Reliance eligibility exists, remember the full package of benefits: review reduced from the standard 150 working days to 60 working days, expert review waived, and about 53,000 baht saved in fees.
- Plan the two segments separately in the project calendar: the 15-day completeness check is a fixed, short allocation, while the substantive review allocation should follow the class ceiling with the 60 percent working estimate described above.
5. Verification checklist
- □ Thai FDA e-Submission completeness check (about 15 days)
- □ Thai FDA review time limit ceilings (Class 1: 200 days / Class 2-3: 250 days / Class 4: 300 days)
- □ Thai FDA Class 1 auto-approval (January 2025, Positive List)
- □ HSA Reliance terms (150 to 60 working days, expert review waived)
- □ Industry experience values: actual periods generally faster than official ceilings (third-tier sources, reference only)
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us